Physician profile
Vipin Gupta
NPI 1851351035
$4,062.05
in general payments reported to CMS, 2019-2025
44 companies · $775 in 2025
The $775 reported for 2025 was more than what 85% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $307 · 2020: $475 · 2021: $663 · 2022: $708 · 2023: $638 · 2024: $496 · 2025: $775.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,822 · Education: $87.49.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,822.13 |
| Education | $87.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,191.86 | 2021-2025 | |
| Biogen, INC. | $343.45 | 2019-2025 | Vumerity, Tysabri |
| Teva Pharmaceuticals USA, INC. | $248.27 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Celgene Corporation | $210.87 | 2021-2024 | Zeposia |
| Lilly USA, LLC | $173.33 | 2019-2025 | Amyvid, Kisunla |
| Eisai INC. | $164.40 | 2019-2025 | |
| Ucb, INC. | $149.64 | 2019-2025 | Fintepla, Briviact |
| Emd Serono, INC. | $147.39 | 2019-2024 | Mavenclad |
| Sk Life Science, INC. | $138.96 | 2020-2025 | |
| Allergan, INC. | $120.49 | 2020 | |
| Novartis Pharmaceuticals Corporation | $113.08 | 2020-2021 | |
| Alexion Pharmaceuticals, INC. | $106.02 | 2020-2025 | Ultomiris |
| Otsuka America Pharmaceutical, INC. | $96.25 | 2023-2025 | Rexulti |
| Pfizer INC. | $75.00 | 2021-2025 | |
| Ani Pharmaceuticals, INC. | $74.21 | 2024-2025 | Purified Cortrophin Gel |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vipin Gupta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.